Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients

NCT00003425 is registered in ClinicalTrials.gov with University of Kentucky as lead sponsor.

NCT NCT00003425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients
Lead sponsor
University of Kentucky
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 1997
Completion date
Not reported
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, leukemia, lymphoma, neuroblastoma, ovarian cancer, sarcoma, unspecified adult solid tumor, protocol specific